Vemurafenib (Zelboraf®) was approved by FDA in 2011 for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation (http://www.cancer.gov/cancertopics/druginfo/fda-vemurafenib). Here, BRAF is linked to metastatic melanoma.